Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Z-6568 in development at Zambon for cardiovascular disorders

April 26, 1996

Tanabe Seiyaku investigates ET antagonists

April 26, 1996

TAC-363 pharmacological profile presented

April 26, 1996

Merck Frosst's new generation of 5-LO inhibitors

April 26, 1996

OPC-14523 improves learning in preclinical models

April 26, 1996

Mitsui Seiyaku describes sigma-opioid antagonist

April 26, 1996

IRI-695 for anxiety and depression

April 26, 1996

TAD-93 in preclinical studies for anxiety

April 26, 1996

MTP inhibitor BMS-201038 in development for hyperlipidemia

April 26, 1996

Otsuka evaluates hypolipidemic agents

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...